ADMA Biologics Inc

Investor‑Litigation Alert: Pomerantz Law Firm investigates ADMA Biologics’ shareholder claims after a $7.3 M net‑sales decline, highlighting potential governance risks and the impact on future growth.

ADMA Biologics’ sudden 16% stock plunge after a short‑seller report and legal scrutiny highlights urgent questions about its finances and future prospects.

ADMA Biologics’ plasma‑derived therapeutics target immunity‑compromised patients, showing solid biotech growth, a balanced P/E and P/B, and 60% upside from its 52‑week low.

ADMA Biologics delivers record FY 2025 revenue and earnings growth, fueled by ASCENIV and a promising SG‑001 pipeline, while disciplined capital strategy drives shareholder value.

ADMA Biologics Inc’s financial results show a mixed bag, with a non-negative earnings per share but a high price-to-earnings ratio, amidst strategic developments aimed at navigating the competitive biotechnology sector.

ADMA Biologics Inc. is a biopharmaceutical company focused on developing and commercializing plasma-derived therapeutics for immunity-compromised patients, with a market capitalization of approximately $4.76 billion USD.

ADMA Biologics Inc. is a biopharmaceutical company focused on developing and commercializing plasma-derived therapeutics for immunity-compromised patients, with a market capitalization of approximately $4.76 billion USD.

ADMA Biologics reports strong Q1 performance, with a 42.17% increase in sales and a significant improvement in earnings, positioning the company for continued growth in the IVIG market.

ADMA Biologics Inc. reported strong Q1 financial performance, with a 42.17% revenue increase and projected EPS of $0.153, positioning the company for continued success in the growing IVIG market.

ADMA Biologics Inc.’s stock reached an all-time high of $24.02 after the FDA approved a new production process, boosting investor confidence and the company’s market position.